Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

BACKGROUND: Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and novel vaccines have been listed by the World Health Organization for emergency use. Additional alternative approaches may better address ongoing vaccination globally, where there remains an inequity in vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Joon Young, Choi, Won Suk, Heo, Jung Yeon, Lee, Jin Soo, Jung, Dong Sik, Kim, Shin-Woo, Park, Kyung-Hwa, Eom, Joong Sik, Jeong, Su Jin, Lee, Jacob, Kwon, Ki Tae, Choi, Hee Jung, Sohn, Jang Wook, Kim, Young Keun, Noh, Ji Yun, Kim, Woo Joo, Roman, François, Ceregido, Maria Angeles, Solmi, Francesca, Philippot, Agathe, Walls, Alexandra C., Carter, Lauren, Veesler, David, King, Neil P., Kim, Hun, Ryu, Ji Hwa, Lee, Su Jeen, Park, Yong Wook, Park, Ho Keun, Cheong, Hee Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304916/
https://www.ncbi.nlm.nih.gov/pubmed/35879941
http://dx.doi.org/10.1016/j.eclinm.2022.101569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304916/
https://www.ncbi.nlm.nih.gov/pubmed/35879941
http://dx.doi.org/10.1016/j.eclinm.2022.101569

Ejemplares similares